Bioiberica excited to welcome pharma stakeholders to its hometown for CPHI

By Liza Laws

- Last updated on GMT

© Getty Images
© Getty Images

Related tags CPHI Pharmaceutical industry Bioiberica Barcelona API

Bioiberica says the excitement for this year’s CPHI has been ‘taken up a notch’ as the company looks forward to welcoming both old and new customers to its hometown, Barcelona.

“CPHI is always a fantastic opportunity to connect with customers – new and old – but the excitement has been taken up a notch this year as we welcome key stakeholders from across the global pharmaceutical landscape to our hometown, Barcelona,” said Luis Solera, CEO at Bioiberica.

The life science company says it is committed to ‘improving the health and well-being of people, animals and plants’ and is excited to participate in the event. It will be showcasing its investment in scientific research, sustainable development and strategic partnerships for a more resilient future, it says.

Alongside its active pharmaceutical ingredient (API) portfolio, the company will present the latest research for its mobility, digestive and skin health branded ingredients. Attendees will also have the opportunity to explore Bioiberica’s newfound focus on advanced wound care which is describes as ‘a captivating area of research in the medical nutrition arena’. Also under the spotlight for the first time, Bioiberica will share scientific data set to unlock a new world of co-innovation possibilities.

Essential APIs

The company will exhibit its essential APIs​ – chondroitin sulfate and glucosamine for the symptomatic treatment of osteoarthritis, thyroid for endocrinology and its flagship ingredient, Heparin.

Visitors to the company’s stand will get the chance to see the latest research supporting the efficacy of its branded ingredients – Collavant n2 (native (undenatured) type 2 collagen), Mobilee (hyaluronic acid matrix ingredient) for joint health and mobility, Dermial (hyaluronic acid matrix ingredient) for skin health and DAOgest (diamine oxidase enzyme) for histamine intolerance.

With sustainability​ top of the agenda for the pharmaceutical industry, Bioiberica will highlight the potential of its latest sustainability initiatives and how they’re helping to enhance its customers’ green credentials in the face of mounting pressures.

Climate neutrality

Attendees can connect with Bioiberica’s experts to learn more about its circular bioeconomy model, targets to obtain 100% renewable electricity by 2024 and 30% less GHG emissions by 2030, and ambitious plans to achieve climate neutrality by 2050.

Solera added: “Progression in the healthcare space hinges on three key pillars: science, sustainability and strategic partnership. CPHI offers us a platform to highlight the substantial strides we’ve made to strengthen these foundations and showcase how we’re supporting our customers in addressing some of the most pressing challenges facing the pharmaceutical industry. Visitors are warmly invited to our booth where we look forward to fostering innovative ideas together.”

Meet Bioiberica at CPHI on stand 7P20 to learn more about the company's APIs and ingredients for human health. 

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us


View more